vs

Side-by-side financial comparison of Atlanticus Holdings Corp (ATLCP) and BIOCRYST PHARMACEUTICALS INC (BCRX). Click either name above to swap in a different company.

Atlanticus Holdings Corp is the larger business by last-quarter revenue ($734.4M vs $406.6M, roughly 1.8× BIOCRYST PHARMACEUTICALS INC). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 4.7%, a 55.8% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs 107.8%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs 58.9%).

Atlanticus Holdings Corp is a U.S.-based financial technology and consumer finance company that provides accessible credit solutions including point-of-sale financing, personal loans, and credit alternatives, primarily serving non-prime and underserved consumer segments across the U.S. It partners with retail merchants and financial institutions to deliver flexible, responsible credit products tailored to borrowers with limited or damaged credit histories.

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

ATLCP vs BCRX — Head-to-Head

Bigger by revenue
ATLCP
ATLCP
1.8× larger
ATLCP
$734.4M
$406.6M
BCRX
Growing faster (revenue YoY)
BCRX
BCRX
+101.3% gap
BCRX
209.1%
107.8%
ATLCP
Higher net margin
BCRX
BCRX
55.8% more per $
BCRX
60.5%
4.7%
ATLCP
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
58.9%
ATLCP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ATLCP
ATLCP
BCRX
BCRX
Revenue
$734.4M
$406.6M
Net Profit
$34.6M
$245.8M
Gross Margin
92.4%
97.7%
Operating Margin
6.3%
64.0%
Net Margin
4.7%
60.5%
Revenue YoY
107.8%
209.1%
Net Profit YoY
11.7%
1017.5%
EPS (diluted)
$1.75
$1.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATLCP
ATLCP
BCRX
BCRX
Q4 25
$734.4M
$406.6M
Q3 25
$494.7M
$159.4M
Q2 25
$394.2M
$163.4M
Q1 25
$345.2M
$145.5M
Q4 24
$353.5M
$131.5M
Q3 24
$351.2M
$117.1M
Q2 24
$316.0M
$109.3M
Q1 24
$290.7M
$92.8M
Net Profit
ATLCP
ATLCP
BCRX
BCRX
Q4 25
$34.6M
$245.8M
Q3 25
$25.0M
$12.9M
Q2 25
$30.6M
$5.1M
Q1 25
$31.5M
$32.0K
Q4 24
$31.0M
$-26.8M
Q3 24
$29.5M
$-14.0M
Q2 24
$24.3M
$-12.7M
Q1 24
$26.2M
$-35.4M
Gross Margin
ATLCP
ATLCP
BCRX
BCRX
Q4 25
92.4%
97.7%
Q3 25
92.1%
98.6%
Q2 25
91.4%
98.3%
Q1 25
90.7%
96.9%
Q4 24
89.9%
95.4%
Q3 24
92.0%
97.3%
Q2 24
91.2%
98.4%
Q1 24
90.8%
98.6%
Operating Margin
ATLCP
ATLCP
BCRX
BCRX
Q4 25
6.3%
64.0%
Q3 25
6.6%
18.6%
Q2 25
10.2%
18.2%
Q1 25
11.8%
14.6%
Q4 24
11.3%
-3.4%
Q3 24
10.6%
6.6%
Q2 24
9.1%
8.0%
Q1 24
11.3%
-15.6%
Net Margin
ATLCP
ATLCP
BCRX
BCRX
Q4 25
4.7%
60.5%
Q3 25
5.0%
8.1%
Q2 25
7.8%
3.1%
Q1 25
9.1%
0.0%
Q4 24
8.8%
-20.4%
Q3 24
8.4%
-12.0%
Q2 24
7.7%
-11.6%
Q1 24
9.0%
-38.1%
EPS (diluted)
ATLCP
ATLCP
BCRX
BCRX
Q4 25
$1.75
$1.13
Q3 25
$1.21
$0.06
Q2 25
$1.51
$0.02
Q1 25
$1.49
$0.00
Q4 24
$1.42
$-0.13
Q3 24
$1.27
$-0.07
Q2 24
$0.99
$-0.06
Q1 24
$1.09
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATLCP
ATLCP
BCRX
BCRX
Cash + ST InvestmentsLiquidity on hand
$621.1M
$274.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$608.7M
$-119.2M
Total Assets
$7.6B
$514.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATLCP
ATLCP
BCRX
BCRX
Q4 25
$621.1M
$274.7M
Q3 25
$425.0M
$212.9M
Q2 25
$329.4M
$260.0M
Q1 25
$350.4M
$295.1M
Q4 24
$375.4M
$320.9M
Q3 24
$308.7M
$96.8M
Q2 24
$350.9M
$78.4M
Q1 24
$444.8M
$84.3M
Stockholders' Equity
ATLCP
ATLCP
BCRX
BCRX
Q4 25
$608.7M
$-119.2M
Q3 25
$589.3M
$-387.9M
Q2 25
$563.3M
$-421.6M
Q1 25
$532.7M
$-451.9M
Q4 24
$492.9M
$-475.9M
Q3 24
$457.7M
$-468.6M
Q2 24
$433.8M
$-475.6M
Q1 24
$416.0M
$-476.2M
Total Assets
ATLCP
ATLCP
BCRX
BCRX
Q4 25
$7.6B
$514.2M
Q3 25
$7.1B
$446.4M
Q2 25
$3.6B
$457.2M
Q1 25
$3.3B
$480.0M
Q4 24
$3.3B
$490.4M
Q3 24
$3.0B
$491.3M
Q2 24
$2.8B
$472.4M
Q1 24
$2.8B
$467.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATLCP
ATLCP
BCRX
BCRX
Operating Cash FlowLast quarter
$266.3M
$292.0M
Free Cash FlowOCF − Capex
$291.2M
FCF MarginFCF / Revenue
71.6%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
7.69×
1.19×
TTM Free Cash FlowTrailing 4 quarters
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATLCP
ATLCP
BCRX
BCRX
Q4 25
$266.3M
$292.0M
Q3 25
$107.5M
$41.6M
Q2 25
$132.7M
$41.3M
Q1 25
$131.6M
$-27.5M
Q4 24
$122.6M
$-5.2M
Q3 24
$112.4M
$8.2M
Q2 24
$115.6M
$-1.4M
Q1 24
$118.8M
$-53.7M
Free Cash Flow
ATLCP
ATLCP
BCRX
BCRX
Q4 25
$291.2M
Q3 25
$40.3M
Q2 25
$41.1M
Q1 25
$-27.7M
Q4 24
$-5.9M
Q3 24
$8.2M
Q2 24
$-1.5M
Q1 24
$-53.9M
FCF Margin
ATLCP
ATLCP
BCRX
BCRX
Q4 25
71.6%
Q3 25
25.3%
Q2 25
25.2%
Q1 25
-19.0%
Q4 24
-4.5%
Q3 24
7.0%
Q2 24
-1.4%
Q1 24
-58.1%
Capex Intensity
ATLCP
ATLCP
BCRX
BCRX
Q4 25
0.2%
Q3 25
0.8%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.3%
Cash Conversion
ATLCP
ATLCP
BCRX
BCRX
Q4 25
7.69×
1.19×
Q3 25
4.30×
3.23×
Q2 25
4.34×
8.12×
Q1 25
4.17×
-859.91×
Q4 24
3.96×
Q3 24
3.80×
Q2 24
4.76×
Q1 24
4.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons